Syndax revenue beat, EPS loss, halts axatilimab IPF program after Phase 2 trial failure
Syndax posts Q3 2026 revenue beat and EPS loss of -$0.55, halts axatilimab IPF program after Phase 2 trial failure
- Q3 2026 revenue was $83.3M, up 82% year over year and above analyst expectations.
- Q3 2026 EPS was -$0.55, missing analyst estimates despite the strong top-line performance.
- Management highlighted accelerating Revuforj sales momentum during the quarter.
- Niktimvo sales also accelerated, supporting the company’s growth trajectory.
- Syndax raised its Niktimvo contribution-margin guidance to the low-to-mid 30% range.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.